Ondine Biomedical, Inc. (DE:VF5)
FRANKFURT:VF5
VF5 Stock Chart & Stats
€0.08
<€0.01(2.47%)
At close: 4:00 PM EST
€0.08
<€0.01(2.47%)
Day’s Range― - ―
52-Week Range€0.07 - €0.20
Previous CloseN/A
Volume0.00
Average Volume (3M)580.00
Market Cap
€88.57M
Enterprise Value€109.78M
Total Cash (Recent Filing)€10.58M
Total Debt (Recent Filing)€413.50K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume0
30 Day Avg. Volume580
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€139.83K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent double-digit revenue growth (2025 ~18% YoY) indicates improving commercial traction for Ondine's antimicrobial products. If sustained, rising sales help spread fixed R&D and G&A, enhancing operating leverage and reducing reliance on external financing over the medium term.
Low LeverageLow reported leverage (debt-to-equity ~0.12) provides financial flexibility to support operations, commercial rollouts, or targeted R&D without heavy interest burdens. This reduced solvency risk preserves optionality for partnerships or incremental investment over the next several quarters.
Focused Technology / Market NicheA specialized platform in antimicrobial photodisinfection targets structural infection-prevention needs in healthcare. That focused, technology-driven model can create durable differentiation, institutional adoption, and recurring demand in clinical settings if regulatory and clinical proof points advance.
Bears Say
Worsening Cash BurnSustained and increasing operating cash outflows (≈ -£23.9M in 2025) materially raise financing risk. Continued burn without rapid revenue scale or cost reduction forces recurrent capital raises, which can dilute shareholders, constrain strategic optionality, and pressure long-term execution.
Declining Gross MarginsA sharp gross margin decline (≈64% to ≈41%) weakens unit economics and suggests pricing or cost structure issues. Lower margins reduce the company's ability to absorb SG&A and R&D, slow progress toward operating profitability, and heighten sensitivity to adverse revenue-mix or cost shocks.
Deep Negative ProfitabilityExtremely negative net margins (~-1,116%) and large operating losses indicate the business remains in high-burn, investment mode. Combined with historical equity volatility and past negative equity episodes, this signals heavy dependence on external capital and elevated dilution and execution risk over coming months.
Ondine Biomedical, Inc. News
VF5 FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest stock price was €0.07 and its highest was €0.20 in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is €88.57M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 94 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.974%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in DE:VF5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth €125.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.62%
12-Months-Change
Fundamentals
Return on Equity
-1411.54%
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---